Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APT-1011 in Eosinophilic Esophagitis
NCT05634746Phase 3Completed
- Sponsor
- Ellodi Pharmaceuticals
- Start
- Dec 2022
- Primary completion
- Aug 2024
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in eosinophilic esophagitis (EoE) comparing APT-1011 with Placebo (2 arms). Primary endpoints: Histological Remission at 24 weeks and Complete Symptomatic Response at 24 weeks. Started Dec 2022; status: completed.
02
Drugs
fluticasone propionate
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05634746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05634746.